These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26924092)

  • 1. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
    Sanyal AJ; Miller V
    Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.
    Do A; Ilagan-Ying YC; Mehal WZ; Lim JK
    Expert Opin Drug Discov; 2021 Feb; 16(2):125-134. PubMed ID: 33086894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 4. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.
    Anania FA; Dimick-Santos L; Mehta R; Toerner J; Beitz J
    Hepatology; 2021 May; 73(5):2023-2027. PubMed ID: 33340111
    [No Abstract]   [Full Text] [Related]  

  • 6. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Neuschwander-Tetri BA; Tonascia J
    Gastroenterology; 2016 Jan; 150(1):11-3. PubMed ID: 26602217
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.
    Williams RN; Filozof C; Goldstein BJ; Cusi K
    Clin Pharmacol Ther; 2017 Apr; 101(4):444-446. PubMed ID: 28032901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).
    Senussi NH; McCarthy DM
    Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic steatohepatitis (NASH) drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2016 Nov; 15(11):745-746. PubMed ID: 27807356
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
    Filozof C; Goldstein BJ; Williams RN; Sanyal A
    Drugs; 2015 Aug; 75(12):1373-92. PubMed ID: 26201461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
    Iakimchuk GN; Gendrikson LN
    Eksp Klin Gastroenterol; 2011; (7):64-9. PubMed ID: 22364002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fatty liver, alcoholic steatohepatitis, and non-alcoholic steatohepatitis].
    Bernal-Reyes R
    Rev Gastroenterol Mex; 2012 Aug; 77 Suppl 1():84-6. PubMed ID: 22939493
    [No Abstract]   [Full Text] [Related]  

  • 14. A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product?
    Altinbas A
    Med Hypotheses; 2017 Oct; 108():159-160. PubMed ID: 29055391
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
    Rowe-Rendleman CL
    Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.
    Athyros VG; Katsiki N; Doumas M
    Curr Vasc Pharmacol; 2018 Jan; 16(2):104-106. PubMed ID: 29210655
    [No Abstract]   [Full Text] [Related]  

  • 18. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.
    Hansen HH; Feigh M; Veidal SS; Rigbolt KT; Vrang N; Fosgerau K
    Drug Discov Today; 2017 Nov; 22(11):1707-1718. PubMed ID: 28687459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape.
    Benda N; Brandt A
    J Biopharm Stat; 2018; 28(1):3-9. PubMed ID: 29065277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.